Oral glucose‐stimulated serum C‐peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment

AIMS/INTRODUCTION: In Japan, liraglutide was recently approved for patients with type 2 diabetes. To our knowledge, there are no markers predicting successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. We therefore assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Hisazumi, Tanaka, Yuki, Yoshida, Syohei, Morita, Yoshikata, Kume, Shinji, Isshiki, Keiji, Araki, Shin‐ichi, Uzu, Takashi, Kashiwagi, Atsunori, Maegawa, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210066/
https://www.ncbi.nlm.nih.gov/pubmed/25411603
http://dx.doi.org/10.1111/jdi.12169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210066/
https://www.ncbi.nlm.nih.gov/pubmed/25411603
http://dx.doi.org/10.1111/jdi.12169

Ejemplares similares